[{"id":"27333119-b7fd-424a-9cb7-3d186e837736","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965114","created_at":"2025-06-14T13:57:06.110Z","updated_at":"2025-06-14T13:57:06.110Z","phase":"Phase 1/2","brief_title":"Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment","source_id_and_acronym":"NCT06965114","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-11"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"1858e4d9-b3bc-4f84-941b-cd90075ac7b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708054","created_at":"2021-01-19T20:51:54.886Z","updated_at":"2025-02-25T14:08:06.998Z","phase":"Phase 2","brief_title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","source_id_and_acronym":"NCT04708054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"acc6da2f-38b7-4ab4-ba2e-48ab70259f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532552","created_at":"2025-02-26T13:41:40.179Z","updated_at":"2025-02-26T13:41:40.179Z","phase":"Phase 2","brief_title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06532552","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 07/29/2024","start_date":" 07/29/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-11-20"},{"id":"4695b874-0dda-42f4-8cd0-07e18a81aa76","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923013","created_at":"2021-01-18T03:34:20.113Z","updated_at":"2024-07-02T16:34:38.035Z","phase":"Phase 2","brief_title":"Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia","source_id_and_acronym":"NCT00923013","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • ITGAX","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 10/20/2008","start_date":" 10/20/2008","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"7729abda-f09b-4e1d-8f6d-26d789073f5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00412594","created_at":"2021-01-18T01:26:56.389Z","updated_at":"2024-07-02T16:35:02.663Z","phase":"Phase 2","brief_title":"Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia","source_id_and_acronym":"NCT00412594","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/10/2004","start_date":" 06/10/2004","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"2e3fc686-f418-46cc-8e0c-83866fce21ca","acronym":"NCI-2014-02324","url":"https://clinicaltrials.gov/study/NCT02250937","created_at":"2021-01-18T10:34:04.951Z","updated_at":"2024-07-02T16:35:07.630Z","phase":"Phase 2","brief_title":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT02250937 - NCI-2014-02324","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 10/27/2014","start_date":" 10/27/2014","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-04-25"},{"id":"59506a1f-78d0-44c7-9ec4-22c51f22d853","acronym":"","url":"https://clinicaltrials.gov/study/NCT04050280","created_at":"2021-01-18T19:51:44.499Z","updated_at":"2024-07-02T16:35:11.259Z","phase":"Phase 2","brief_title":"CLAG-GO for Patients With Persistent, Relapsed or Refractory AML","source_id_and_acronym":"NCT04050280","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Mylotarg (gemtuzumab ozogamicin) • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-04-05"},{"id":"613e6d83-8a24-4773-9fa7-ac0078156fbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02131753","created_at":"2021-01-18T09:53:21.117Z","updated_at":"2024-07-02T16:35:48.422Z","phase":"Phase 2/3","brief_title":"Therapy Optimisation for the Treatment of Hairy Cell Leukemia","source_id_and_acronym":"NCT02131753","lead_sponsor":"University of Giessen","biomarkers":" CD19 • IL2RA • ITGAE • ISG20","pipe":"","alterations":" ","tags":["CD19 • IL2RA • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/01/2004","start_date":" 05/01/2004","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-05-10"},{"id":"55b7a154-a1a8-4a84-8f77-68505d4bda6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05330377","created_at":"2022-04-15T12:53:52.419Z","updated_at":"2025-02-25T15:27:20.156Z","phase":"Phase 1","brief_title":"GM-CLAG in Relapsed/Refractory FLT3-mutated AML","source_id_and_acronym":"NCT05330377","lead_sponsor":"Ayman H Qasrawi","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • mitoxantrone • cladribine • Neupogen (filgrastim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 05/30/2027","primary_completion_date":" 05/30/2027","study_txt":" Completion: 05/30/2032","study_completion_date":" 05/30/2032","last_update_posted":"2023-04-25"},{"id":"f5563541-42ba-4928-8bc5-ee322d350ebf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199030","created_at":"2021-09-05T08:53:21.634Z","updated_at":"2024-07-02T16:35:52.983Z","phase":"Phase 2","brief_title":"Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath","source_id_and_acronym":"NCT00199030","lead_sponsor":"Goethe University","biomarkers":" CD52","pipe":" | ","alterations":" CD52 expression","tags":["CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • cladribine"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 04/01/2008","study_completion_date":" 04/01/2008","last_update_posted":"2023-03-20"},{"id":"f7b6022b-77ea-42fa-ac80-1a76333093f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03926624","created_at":"2021-01-18T19:20:53.790Z","updated_at":"2024-07-02T16:36:02.107Z","phase":"Phase 3","brief_title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","source_id_and_acronym":"NCT03926624","lead_sponsor":"Delta-Fly Pharma, Inc.","biomarkers":" IDH1 • BCL2","pipe":"","alterations":" ","tags":["IDH1 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • decitabine • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • radgocitabine (DFP-10917)"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 11/22/2019","start_date":" 11/22/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-10-20"},{"id":"e5847a40-5b30-420c-89e4-cd5a71acd410","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756572","created_at":"2022-01-21T22:01:58.163Z","updated_at":"2024-07-02T16:36:20.983Z","phase":"Phase 2","brief_title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT02756572","lead_sponsor":"University of Washington","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sirolimus • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2016","start_date":" 09/22/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2021-11-08"},{"id":"04c14456-3c0d-4ac4-ab2d-fa7eaa7575f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04880746","created_at":"2021-05-11T11:52:53.294Z","updated_at":"2024-07-02T16:36:30.510Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study","source_id_and_acronym":"NCT04880746","lead_sponsor":"Ruijin Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 266","initiation":"Initiation: 10/17/2020","start_date":" 10/17/2020","primary_txt":" Primary completion: 10/17/2024","primary_completion_date":" 10/17/2024","study_txt":" Completion: 10/17/2025","study_completion_date":" 10/17/2025","last_update_posted":"2021-05-11"},{"id":"9f630e98-0718-432f-9648-59a5e95c6779","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980395","created_at":"2021-01-18T03:49:32.383Z","updated_at":"2024-07-02T16:36:52.020Z","phase":"Phase 2","brief_title":"Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma","source_id_and_acronym":"NCT00980395","lead_sponsor":"University of Arizona","biomarkers":" BCL2 • CD20","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cladribine"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/07/2009","start_date":" 07/07/2009","primary_txt":" Primary completion: 09/12/2014","primary_completion_date":" 09/12/2014","study_txt":" Completion: 08/14/2018","study_completion_date":" 08/14/2018","last_update_posted":"2019-12-30"},{"id":"56907eaa-2dac-441a-9353-c9b395743cda","acronym":"","url":"https://clinicaltrials.gov/study/NCT00053027","created_at":"2021-01-18T00:05:58.307Z","updated_at":"2024-07-02T16:37:27.204Z","phase":"Phase 2","brief_title":"Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00053027","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CCND1","pipe":"","alterations":" ","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2003","start_date":" 02/01/2003","primary_txt":" Primary completion: 01/01/2006","primary_completion_date":" 01/01/2006","study_txt":" Completion: 11/01/2009","study_completion_date":" 11/01/2009","last_update_posted":"2016-12-07"}]